Skip to main content
SpringerLink
Log in

Colon Cancer

  • Chapter
  • First Online:
Surgical Oncology Manual

  • 1407 Accesses

Abstract

Colorectal cancer is the third most common cancer and second leading cause of death from cancer in Canada. Screening efforts should be tailored depending on risk factors such as family history, age, and history of polyps. Testing for hereditary colorectal cancer syndromes with immunohistochemistry allows for appropriate screening of syndrome-related malignancies and genetic counselling. Here we review screening, multidisciplinary treatment, and surveillance of colon cancer based on current evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian cancer statistics 2014. Toronto, ON: Canadian Cancer Society; 2014.

    Google Scholar 

  2. Colorectal Cancer Staging and Survival. Toronto, ON: Canadian Partnership Against Cancer; 2010.

    Google Scholar 

  3. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103(6):1541–9.

    Article  PubMed  Google Scholar 

  4. Holme O, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database of Syst Rev. 2013;9:CD009259.

    Google Scholar 

  5. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312(6):606–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ. 2014;348:g2467.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104(3):739–50.

    Article  PubMed  Google Scholar 

  8. Rabeneck L, Paszat LF, Saskin R, Stukel TA. Association between colonoscopy rates and colorectal cancer mortality. Am J Gastroenterol. 2010;105(7):1627–32.

    Article  PubMed  Google Scholar 

  9. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150(1):1–8.

    Article  PubMed  Google Scholar 

  10. Tinmouth J, Kennedy EB, Baron D, Burke M, Feinberg S, Gould M, et al. Colonoscopy quality assurance in Ontario: systematic review and clinical practice guideline. Can J Gastroenterol Hepatol. 2014;28(5):251–74.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143(3):844–57.

    Article  PubMed  Google Scholar 

  12. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European society for medical oncology clinical practice guidelines. J Clin Oncol. 2015;33(2):209–17.

    Article  PubMed  Google Scholar 

  16. Matloff J, Lucas A, Polydorides AD, Itzkowitz SH. Molecular tumor testing for Lynch syndrome in patients with colorectal cancer. J Natl Compr Canc Netw. 2013;11(11):1380–5.

    PubMed  Google Scholar 

  17. Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Paya A, Brea A, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 2012;61(6):865–72.

    Article  CAS  PubMed  Google Scholar 

  18. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;1:002200.

    Google Scholar 

  19. Figueredo A, Rumble RB, Maroun J, et al. The members of the Gastrointestinal Cancer Disease Site Group. Follow-up of patients with curatively resected colorectal cancer. Practice Guideline Report #2–9. June 16, 2010.

    Google Scholar 

  20. Earle C, Annis R, Sussman J, Haynes AE, Vafaei A. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer. Toronto, ON: Cancer Care Ontario; 2012. Program in Evidence-based Care Evidence-Based Series No.: 26-2.

    Google Scholar 

  21. Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.

    Article  CAS  PubMed  Google Scholar 

  22. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343–51.

    Google Scholar 

  23. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.

    Article  CAS  PubMed  Google Scholar 

  24. Nivatvongs S, Rojanasakul A, Reiman HM, et al. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum. 1991;34(4):323–8.

    Article  CAS  PubMed  Google Scholar 

  25. Smith A, Rumble RB, Langer B, et al. Laparoscopic surgery for cancer of the colon. Toronto, ON: Cancer Care Ontario; 2005. Program in Evidence-Based Care. Evidence-based Series #2-20-2.

    Google Scholar 

  26. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350(20):2050–9.

    Article  Google Scholar 

  27. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25(21):3061–8.

    Article  PubMed  Google Scholar 

  28. Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359(9325):2224–9.

    Article  PubMed  Google Scholar 

  29. Kuhry E, Schwenk W, Gaupset R, et al. Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. Cancer Treat Rev. 2008;34(6):498–504.

    Article  PubMed  Google Scholar 

  30. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21(15):2912–9.

    Article  PubMed  Google Scholar 

  31. Smith AJ, Driman DK, Spithoff K, et al. Guideline for optimization of colorectal cancer surgery and pathology. J Surg Oncol. 2010;101(1):5–12.

    Article  PubMed  Google Scholar 

  32. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50(11):1783–99.

    Article  PubMed  Google Scholar 

  33. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31(35):4465–70.

    Article  PubMed  Google Scholar 

  34. Bowne WB, Lee B, Wong WD, et al. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases. Dis Colon Rectum. 2005;48(5):897–909.

    Article  PubMed  Google Scholar 

  35. Smith AJ, Driman DK, Spithoff K, McLeod R, Hunter A, Rumble RB, et al. Optimization of surgical and pathological quality performance in radical surgery for colon and rectal cancer: margins and lymph nodes. Toronto, ON: Cancer Care Ontario; 2008. [In review 2013 Dec]. Program in Evidence-based Care Evidence-based Series No.: 7-14 IN REVIEW.

    Google Scholar 

  36. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    Article  CAS  PubMed  Google Scholar 

  37. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.

    Article  CAS  PubMed  Google Scholar 

  38. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9. Erratum appears in J Clin Oncol. 2009;27(4):653.

    Article  CAS  PubMed  Google Scholar 

  39. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.

    Article  PubMed  Google Scholar 

  40. Faron M, Pignon JP, Malka D, Bourredjem A, Douillard JY, Adenis A, et al. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer. 2015;51(2):166–76.

    Article  PubMed  Google Scholar 

  41. Fleshman J, Sargent DJ, Green E, et al. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg. 2007;246(4):655–62. discussion 662–4.

    Article  PubMed  Google Scholar 

  42. Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 2009;10(1):44–52.

    Article  PubMed  Google Scholar 

  43. Lacy AM, Delgado S, Castells A, et al. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg. 2008;248(1):1–7.

    Article  PubMed  Google Scholar 

  44. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.

    Article  CAS  PubMed  Google Scholar 

  45. Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353–60.

    Article  CAS  PubMed  Google Scholar 

  46. Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23(5):1190–7.

    Article  CAS  PubMed  Google Scholar 

  47. Cukier M, Smith AJ, Milot L, Chu W, Chung H, Fenech D, et al. Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience. Eur J Surg Oncol. 2012;38(8):677–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Surgical Oncology, University of Toronto, Toronto, ON, Canada

    Usmaan Hameed M.D., F.R.C.S.C. (Fellow)

  2. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Nancy Baxter MD, PhD, FRCSC, FACS, Zane Cohen M.D., F.R.C.S.C., F.A.C.S., Robert Gryfe M.D., Ph.D., F.R.C.S.C., Robin McLeod M.D., F.R.C.S.C., F.A.C.S. & Fayez A. Quereshy M.D., M.B.A., F.R.C.S.C.

Authors
  1. Usmaan Hameed M.D., F.R.C.S.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy Baxter MD, PhD, FRCSC, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zane Cohen M.D., F.R.C.S.C., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert Gryfe M.D., Ph.D., F.R.C.S.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robin McLeod M.D., F.R.C.S.C., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fayez A. Quereshy M.D., M.B.A., F.R.C.S.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Usmaan Hameed M.D., F.R.C.S.C. .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Toronto, Toronto, Ontario, Canada

    Frances C. Wright

  2. Department of Surgery, University of Toronto, Toronto, Ontario, Canada

    Jaime Escallon

  3. Department of Surgical Oncology, National Cancer Institute, Panama City, Panama

    Moises Cukier

  4. General Surgical Oncology, University of Toronto, 1X5, Ontario, Canada

    Melanie E. Tsang

  5. General Surgical Oncology, University of Toronto, Toronto, Ontario, Canada

    Usmaan Hameed

Rights and permissions

Reprints and permissions

Copyright information

© 2016 University of Toronto General Surgery Oncology Program

About this chapter

Cite this chapter

Hameed, U., Baxter, N., Cohen, Z., Gryfe, R., McLeod, R., Quereshy, F.A. (2016). Colon Cancer. In: Wright, F., Escallon, J., Cukier, M., Tsang, M., Hameed, U. (eds) Surgical Oncology Manual. Springer, Cham. https://doi.org/10.1007/978-3-319-26276-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26276-5_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26274-1

  • Online ISBN: 978-3-319-26276-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation